QR Code

Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway

PARP inhibitors have changed the management of advanced high-grade epithelial ovarian cancer (EOC), especially homologous recombinant (HR)-deficient advanced high-grade EOC. However, the effect of PARP inhibitors on HR-proficient (HRP) EOC is limited. Thus, new therapeutic strategy for HRP EOC is de...

Full description

Saved in:
Main Authors: Yasushi Iida, Nozomu Yanaihara, Yuki Yoshino, Misato Saito, Ryosuke Saito, Junya Tabata, Ayako Kawabata, Masataka Takenaka, Natsuko Chiba, Aikou Okamoto
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Oncology
Subjects:
ovarian cancer
olaparib
bevacizumab
homologous recombinant proficient
CRY1
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1302850/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items